UK markets close in 7 hours 30 minutes
  • FTSE 100

    -18.36 (-0.24%)
  • FTSE 250

    +61.14 (+0.31%)
  • AIM

    -0.95 (-0.10%)

    -0.0002 (-0.02%)

    -0.0024 (-0.20%)

    -437.94 (-2.20%)
  • CMC Crypto 200

    -15.88 (-2.77%)
  • S&P 500

    -31.16 (-0.72%)
  • DOW

    -171.69 (-0.50%)

    -0.11 (-0.12%)

    -1.10 (-0.06%)
  • NIKKEI 225

    -280.63 (-0.96%)

    -191.15 (-0.96%)
  • DAX

    +55.18 (+0.40%)
  • CAC 40

    +7.80 (+0.12%)

Insights on the Rat and Mouse Model Global Market to 2028 - by Type, Technology, Service, Application, End-use and Region -

·5-min read

DUBLIN, December 06, 2021--(BUSINESS WIRE)--The "Rat And Mouse Model Market Size, Share & Trends Analysis Report By Type (Knockout, Knock-in), By Technology, By Service (Breeding, Rederivation), By Application (COVID-19, CVS), By End-use, And Segment Forecasts, 2021 - 2028" report has been added to's offering.

The global rat and mouse model market size is anticipated to reach USD 2.9 billion by 2028, according to a new report by the publisher. The market is expected to expand at a CAGR of 5.5% from 2021 to 2028.

Recent advancements in the field of genetic engineering including piggyBac technologies, Cas-CLOVER, and CRISPR/Cas9 facilitate researchers to develop immunodeficient rat models which can be used for human cell/tissue regeneration and transplants.

Key companies have leveraged advanced technologies such as machine learning, big data analytics, genome engineering tools, and next-generation sequencing technology to develop mouse and rat models with more human-like microbiomes, immune systems, and genetic backgrounds. For instance, models from the Jackson Laboratory reflect the genetic diversity showcased by the human population.

Market participants are focused to develop novel methods to certify that in vivo and in vitro testing complement each other. In this regard, an increase in the adoption rate of organoid systems has been observed. These systems guide engineering as well as enhance the use and selection of animal models. Moreover, the rise in utilization of mouse model in the analysis of SARS-CoV-2 infection in upper and lower respiratory tract infections drives the global market.

Companies Mentioned

  • Charles River Laboratories, Inc.

  • The Jackson Laboratory.

  • Laboratory Corporation of America

  • Perkin Elmer (Horizon Discovery Group plc)

  • genOway

  • Envigo

  • Janvier Labs

  • Taconic Biosciences, Inc.

  • Biomere (Biomedical Research Models, Inc.)

  • Transposagen Biopharmaceuticals, Inc.

Rat And Mouse Model Market Report Highlights

  • The outbred model system generated the largest revenue amongst model type as outbred strains are genetically diverse and feature well-characterized, stable genetic variation which accurately reflects the genetic structure of human populations

  • Therefore, outbred strains such as the Diversity Outbred (DO) mice are used to analyze the genetic complexity behind cancer, autoimmune disorders, addiction, obesity, heart disease, diabetes, and Alzheimer's disease

  • The CRISPR/Cas9 segment is anticipated to witness the fastest CAGR from 2021 to 2028 as CRISPR/Cas9 can target any definite exons for exclusion or inclusion within an mRNA

  • Additionally, the use of the CRISPR/Cas9 system to generate the knockout mouse models simplifies the whole process and reduces the timeframe from 1-2 years to 6 months

  • The cryopreservation segment is expected to gain significant traction during the forecast period

  • The technique provides a fast and reliable procedure for archiving sperm and embryos of valuable mice strains

  • Cancer is the largest revenue-generating application segment as the mouse and human genomes are homologous. Thus, it provides a good tool for cancer research as well as for drug discovery

  • Pharmaceutical and biotechnology companies dominated the end-use segment in terms of revenue share in 2020. Rat and mice models are some of the most used animal models in drug discovery

  • Techniques such as CRISPR/Cas9, homologous recombination, and random transgenesis help the biotech and pharma companies to analyze hypotheses or to generate rat models for human diseases

  • Genetically engineered models play a vital role to assess and characterize target identification, disease pathology, and in vivo assessment of new molecular entities

  • Profitable opportunities offered by the developing nations and have attracted investments from global companies in the Asia Pacific region

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope

Chapter 4 Industry Outlook

4.1 Market Variable Analysis

4.1.1 Rise in adoption of personalized medicine and subsequent demand of rat & mouse models for precision medicine approaches

4.1.2 Application of genome editing tools for generation of rodent models

4.1.3 Increase in the number of research activities involving the use of rat and mouse models

4.1.4 Grants & investments

4.2 Market Restraint Analysis

4.2.1 Ethical issues pertaining to the use of animals for research

4.2.2 Rise in adoption of Zebrafish models for biomedical research

4.3 Market Opportunity Analysis

4.3.1 Rise in demand for humanized rat & mouse models

4.3.2 Utility of rat/mouse models to examine the pathogenesis of SARS-CoV-2

4.4 Market Challenge Analysis

4.4.1 Alternatives to Animal Testing In Vitro Testing Computer (in Silico) Modeling

4.4.2 Speculations regarding ban on animal testing

Chapter 5 Business Environment Analysis

5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)

5.2 Porter's Five Forces Analysis

Chapter 6 Competitive Analysis

6.1 Recent Developments & Impact Analysis, by Key Market Participants

6.2 Mergers and acquisitions

6.3 Partnerships

6.4 Agreements

6.5 Synergies, Collaborations, and other initiatives

Chapter 7 Type Business Analysis

Chapter 8 Technology Business Analysis

Chapter 9 Service Business Analysis

Chapter 10 Application Business Analysis

Chapter 11 End-use Business Analysis

Chapter 12 Regional Business Analysis

Chapter 13 Company Profile

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting